The FDA has launched a pilot program to speed regulatory review of generic drugs manufactured in the U.S. using domestically sourced active pharmaceutical ingredients (APIs). This initiative aims to incentivize onshoring of pharmaceutical manufacturing, reduce foreign dependence, and enhance drug supply chain resilience. The abbreviated new drug application (ANDA) program expedites evaluations for qualified generics, supporting national goals for drug accessibility and security amid global supply challenges.